<DOC>
	<DOCNO>NCT01233115</DOCNO>
	<brief_summary>This study investigate whether association LOC387715/HTRA1 variant response treatment combine photodynamic therapy intravitreal bevacizumab patient polypoidal choroidal vasculopathy .</brief_summary>
	<brief_title>LOC387715/HTRA1 Combined Photodynamic Therapy With Intravitreal Bevacizumab Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>This retrospective cohort study comprise 70 eye treat polypoidal choroidal vasculopathy combine photodynamic therapy intravitreal bevacizumab injection . Patients genotyped LOC387715 ( rs10490924 ) HTRA1 gene polymorphism ( rs11200638 ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient older 60 year age onset polyplike terminal aneurysmal dilation without branch vascular network indocyanine green angiography ( ICGA ) subretinal reddishorange protrusion correspond polyplike lesion patient combined photodynamic therapy intravitreal bevacizumab injection , follow 12 month first treatment patient retinal choroidal disease include pathologic myopia , angioid streak , idiopathic choroidal neovascularization ( CNV ) , presume ocular histoplasmosis , secondary CNV patient refuse genotypic analysis</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>